Vancomycin pharmacokinetics during high-volume continuous venovenous hemofiltration in critically ill septic patients. 2014

Nadezda Petejova, and Arnost Martinek, and Jana Zahalkova, and Jana Duricova, and Hana Brozmannova, and Karel Urbanek, and Milan Grundmann, and Jiri Plasek, and Ivana Kacirova
Department of Internal Medicine, Faculty of Medicine, University of Ostrava and University Hospital Ostrava, Czech Republic.

OBJECTIVE To assess the influence of continuous venovenous hemofiltration (CVVH) at a filtration rate of 45 mL/kg/h on vancomycin pharmacokinetics in critically ill septic patients with acute kidney injury (AKI). METHODS Seventeen adult septic patients with acute kidney injury treated with CVVH and vancomycin were included. All patients received first dose of 1.0 g intravenously followed by 1.0 g/12 h if not adjusted. In sixteen patients vancomycin was introduced on the day of the start of CRRT therapy. Blood samples and ultrafiltrates were obtained before and 0.5, 1, 6 and 12 h after vancomycin administration. RESULTS On the first day, the median total vancomycin clearance (Cltot) was 0.89 mL/min/kg (range 0.31 - 2.16). CRRT clearance accounted for around 50-60% of the total clearance of vancomycin found in a population with normal renal function (0.97 mL/min/kg). Vancomycin serum concentrations after the first dose were below the required target of 10 mg/L as early as 6 h in 10 patients, AUC0-24/MIC ≥ 400 ratio was achieved in 10 patients on the first day. CONCLUSIONS CVVH at a filtration rate of 45 mL/kg/h leads to high and rapid extracorporeal removal of vancomycin in critically ill patients. Due to the rapid change in patient clinical status it was impossible to predict a fixed dosage regimen. We recommend blood sampling as early as 6 h after first vancomycin dose with maintenance dose based on vancomycin serum level monitoring.

UI MeSH Term Description Entries
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D011446 Prospective Studies Observation of a population for a sufficient number of persons over a sufficient number of years to generate incidence or mortality rates subsequent to the selection of the study group. Prospective Study,Studies, Prospective,Study, Prospective
D005260 Female Females
D006440 Hemofiltration Extracorporeal ULTRAFILTRATION technique without HEMODIALYSIS for treatment of fluid overload and electrolyte disturbances affecting renal, cardiac, or pulmonary function. Arteriovenous Hemofiltration,Venovenous Hemofiltration,Arteriovenous Hemofiltrations,Hemofiltration, Arteriovenous,Hemofiltration, Venovenous,Hemofiltrations,Venovenous Hemofiltrations
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults
D000368 Aged A person 65 years of age or older. For a person older than 79 years, AGED, 80 AND OVER is available. Elderly
D000900 Anti-Bacterial Agents Substances that inhibit the growth or reproduction of BACTERIA. Anti-Bacterial Agent,Anti-Bacterial Compound,Anti-Mycobacterial Agent,Antibacterial Agent,Antibiotics,Antimycobacterial Agent,Bacteriocidal Agent,Bacteriocide,Anti-Bacterial Compounds,Anti-Mycobacterial Agents,Antibacterial Agents,Antibiotic,Antimycobacterial Agents,Bacteriocidal Agents,Bacteriocides,Agent, Anti-Bacterial,Agent, Anti-Mycobacterial,Agent, Antibacterial,Agent, Antimycobacterial,Agent, Bacteriocidal,Agents, Anti-Bacterial,Agents, Anti-Mycobacterial,Agents, Antibacterial,Agents, Antimycobacterial,Agents, Bacteriocidal,Anti Bacterial Agent,Anti Bacterial Agents,Anti Bacterial Compound,Anti Bacterial Compounds,Anti Mycobacterial Agent,Anti Mycobacterial Agents,Compound, Anti-Bacterial,Compounds, Anti-Bacterial
D014640 Vancomycin Antibacterial obtained from Streptomyces orientalis. It is a glycopeptide related to RISTOCETIN that inhibits bacterial cell wall assembly and is toxic to kidneys and the inner ear. AB-Vancomycin,Diatracin,VANCO-cell,Vanco Azupharma,Vanco-saar,Vancocin,Vancocin HCl,Vancocine,Vancomicina Abbott,Vancomicina Chiesi,Vancomicina Combino Phar,Vancomicina Norman,Vancomycin Hexal,Vancomycin Hydrochloride,Vancomycin Lilly,Vancomycin Phosphate (1:2),Vancomycin Phosphate (1:2), Decahydrate,Vancomycin Sulfate,Vancomycin-ratiopharm,Vancomycine Dakota,Hydrochloride, Vancomycin,Sulfate, Vancomycin

Related Publications

Nadezda Petejova, and Arnost Martinek, and Jana Zahalkova, and Jana Duricova, and Hana Brozmannova, and Karel Urbanek, and Milan Grundmann, and Jiri Plasek, and Ivana Kacirova
February 2002, Pharmacotherapy,
Nadezda Petejova, and Arnost Martinek, and Jana Zahalkova, and Jana Duricova, and Hana Brozmannova, and Karel Urbanek, and Milan Grundmann, and Jiri Plasek, and Ivana Kacirova
February 2023, Antiviral therapy,
Nadezda Petejova, and Arnost Martinek, and Jana Zahalkova, and Jana Duricova, and Hana Brozmannova, and Karel Urbanek, and Milan Grundmann, and Jiri Plasek, and Ivana Kacirova
September 2004, British journal of clinical pharmacology,
Nadezda Petejova, and Arnost Martinek, and Jana Zahalkova, and Jana Duricova, and Hana Brozmannova, and Karel Urbanek, and Milan Grundmann, and Jiri Plasek, and Ivana Kacirova
July 2010, Antimicrobial agents and chemotherapy,
Nadezda Petejova, and Arnost Martinek, and Jana Zahalkova, and Jana Duricova, and Hana Brozmannova, and Karel Urbanek, and Milan Grundmann, and Jiri Plasek, and Ivana Kacirova
December 1997, Antimicrobial agents and chemotherapy,
Nadezda Petejova, and Arnost Martinek, and Jana Zahalkova, and Jana Duricova, and Hana Brozmannova, and Karel Urbanek, and Milan Grundmann, and Jiri Plasek, and Ivana Kacirova
July 2016, European journal of clinical pharmacology,
Nadezda Petejova, and Arnost Martinek, and Jana Zahalkova, and Jana Duricova, and Hana Brozmannova, and Karel Urbanek, and Milan Grundmann, and Jiri Plasek, and Ivana Kacirova
October 2014, International journal of antimicrobial agents,
Nadezda Petejova, and Arnost Martinek, and Jana Zahalkova, and Jana Duricova, and Hana Brozmannova, and Karel Urbanek, and Milan Grundmann, and Jiri Plasek, and Ivana Kacirova
January 1991, Contributions to nephrology,
Nadezda Petejova, and Arnost Martinek, and Jana Zahalkova, and Jana Duricova, and Hana Brozmannova, and Karel Urbanek, and Milan Grundmann, and Jiri Plasek, and Ivana Kacirova
September 2001, Acta anaesthesiologica Scandinavica,
Nadezda Petejova, and Arnost Martinek, and Jana Zahalkova, and Jana Duricova, and Hana Brozmannova, and Karel Urbanek, and Milan Grundmann, and Jiri Plasek, and Ivana Kacirova
January 2019, Blood purification,
Copied contents to your clipboard!